• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday

    9/13/22 5:14:59 AM ET
    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Automotive Aftermarket
    Consumer Discretionary
    Get the next $AKTX alert in real time by email

    Gainers

    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
    • InMed Pharmaceuticals Inc. (NASDAQ:INM) gained 70.4% to close at $18.78 after the company on Friday announced a $6 million private placement priced at $8.68 per share.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares surged 65% to close at $38.11 on Monday after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
    • PolyPid Ltd. (NASDAQ:PYPD) gained 58.3% to close at $1.71. The company earlier announced it will present Phase 2 D-PLEX₁₀₀ data at the European Society for Coloproctology Scientific Conference next week.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) shares gained 38.1% to close at $7.72. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference later today.
    • PaxMedica, Inc. (NASDAQ:PXMD) rose 36.6% to settle at $4.33 after TardiMed Sciences' Michael Derby on Friday disclosed a 63.4% active stake in the company.
    • Allego N.V. (NYSE:ALLG) jumped 33.5% to close at $5.90.
    • IDEAYA Biosciences, Inc. (NASDAQ:IDYA) jumped 30.7% to close at $12.09. IDEAYA Biosciences disclosed interim Phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) climbed 30.4% to close at $1.50 after the company said Rubraca (Rucaparib) as first-line maintenance treatment improves progression-free survival in women with advanced ovarian cancer across disease risk subgroups.
    • Annovis Bio, Inc. (NYSE:ANVS) gained 29.5% to settle at $19.82 on above-average volume.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) surged 27.7% to close at $2.86.
    • IHS Holding Limited (NYSE:IHS) jumped 24.9% to close at $7.83. IHS Holding, last month, said Q2 EPS results down year-over-year.
    • Gogoro Inc. (NASDAQ:GGR) gained 21.3% to close at $5.25. Gogoro recently launched its battery-swapping system and Smart scooters in the Tel Aviv metropolitan area.
    • ImmunityBio, Inc. (NASDAQ:IBRX) jumped 20.9% to close at $5.61.
    • POINT Biopharma Global Inc. (NASDAQ:PNT) rose 19.8% to close at $10.27 after the company published a poster at ESMO Congress 2022 highlighting updated safety and efficacy data from its Phase 3 SPLASH trial of PNT2002 in metastatic castration-resistant prostate cancer.
    • Rackspace Technology, Inc. (NASDAQ:RXT) gained 18.8% to settle at $6.32.
    • Magic Empire Global Limited (NASDAQ:MEGL) jumped 17.9% to close at $6.00.
    • Regulus Therapeutics Inc. (NASDAQ:RGLS) rose 16.9% to close at $1.94 after the company announced topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429. The study demonstrated that RGLS8429 has a favorable safety and PK profile.
    • TuanChe Limited (NASDAQ:TC) gained 16.8% to close at $3.20.
    • Asana, Inc. (NYSE:ASAN) climbed 16.4% to close at $28.71. Asana’s President, CEO and Director Dustin Moskovitz bought a total of 19,273,127 shares at an average price of $18.16.
    • Carvana Co. (NYSE:CVNA) gained 15.5% to close at $42.28. Piper Sandler upgraded Carvana from Neutral to Overweight and lowered the price target from $98 to $73.
    • Ra Medical Systems, Inc. (NYSE:RMED) surged 15.1% to close at $0.1675 after the company announced a merger agreement with Catheter Precision. Catheter Precision will become a wholly owned subsidiary of Ra Medical.
    • Finance Of America Companies Inc. (NYSE:FOA) gained 15.1% to settle at $1.60.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) gained 14.7% to close at $0.6650.
    • American Rebel’s CEO Andy Ross issued a corporate update in letter to stockholders.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) jumped 13.6% to close at $26.46.
    • NIO Inc. (NYSE:NIO) surged 13.5% to close at $21.75 following positive analyst coverage from Deutsche Bank and BofA.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) rose 13% to close at $1.13.
    • SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) gained 12.8% to close at $31.98 after the company announced data from the Phase 3 DeFi trial of nirogacestat in adult patients with desmoid tumors showed nirogacestat treatment resulted in rapid, sustained and statistically significant improvements in primary and all key secondary efficacy endpoints.
    • Cardlytics, Inc. (NASDAQ:CDLX) rose 12.2% to close at $14.31.
    • Auddia Inc. (NASDAQ:AUUD) gained 12% to settle at $1.40.
    • Sigma Lithium Corporation (NASDAQ:SGML) gained 11.4% to close at $27.81.
    • Ribbon Communications Inc. (NASDAQ:RBBN) jumped 10.5% to close at $3.57.
    • Quhuo Limited (NASDAQ:QH) shares gained 10.2% to close at $3.03 after the company on Friday said it has determined not to proceed with its proposed offering and sale of securities.
    • Lucid Group, Inc. (NASDAQ:LCID) jumped 9.7% to close at $16.55 after RF Lafferty initiated coverage on the stock with a Buy rating and a $19 price target.
    • NetScout Systems, Inc. (NASDAQ:NTCT) rose 9.4% to close at $33.60. The company, last month, posted upbeat quarterly earnings.
    • Reborn Coffee, Inc. (NASDAQ:REBN) rose 8.4% to close at $2.57. Dennis R Egidi recently reported a 9.5% stake in Reborn Coffee.
    • Wayfair Inc. (NYSE:W) gained 7.7% to settle at $55.95 amid overall market strength as investors await this week's inflation data.
    • Genenta Science S.p.A. (NASDAQ:GNTA) rose 7.5% to close at $5.15.
    • Hyperfine, Inc. (NASDAQ:HYPR) gained 7.4% to close at $1.31 after declining 6% on Friday. Hyperfine, last month, reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
    • Eve Holding, Inc. (NYSE:EVEX) gained 5.7% to close at $8.15. United recently announced a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
    • Bristol-Myers Squibb Company (NYSE:BMY) gained 3.1% to settle at $72.36. The FDA approved Bristol Myers Squibb Co's Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Atlantic Equities maintained Bristol-Myers Squibb with an Overweight and raised the price target from $83 to $87.

     

    Losers

    • Tuesday Morning Corporation (NASDAQ:TUEM) dipped 31.2% to close at $0.1937. The company on Friday announced it has entered into an agreement to secure $32 million in convertible debt financing.
    • WeTrade Group, Inc. (NASDAQ:WETG) dropped 30.2% to close at $1.11 on above-average volume.
    • Akari Therapeutics, Plc (NASDAQ:AKTX) shares fell 27.9% to close at $0.75 on Monday after the company announced a $12.75 million registered direct offering.
    • Yoshiharu Global Co. (NASDAQ:YOSH) shares fell 26.9% to close at $3.05. The company, on Friday, priced its IPO at $4 per share.
    • Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) fell 25.9% to close at $1.40. Ayala Pharmaceuticals presented interim data from RINGSIDE pivotal Phase 2/3 trial of AL102 show confirmed partial response in desmoid tumors, at ESMO Congress.
    • Intellinetics, Inc. (NASDAQ:INLX) dropped 22.9% to settle at $4.58 as the stock gave up last week's gains. The company recently announced an uplisting to the NYSE.
    • Goosehead Insurance, Inc (NASDAQ:GSHD) fell 21.9% to close at $42.28. Goosehead Insurance named Mark Jones, Jr as new CFO.
    • ShiftPixy, Inc. (NASDAQ:PIXY) declined 20.8% to close at $27.28 amid profit taking after the stock surged last week following the company's announcement it plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
    • Entrada Therapeutics, Inc. (NASDAQ:TRDA) fell 20.2% to close at $11.91. Entrada Therapeutics, last month, posted a Q2 loss of $0.74 per share.
    • Leap Therapeutics, Inc. (NASDAQ:LPTX) fell 20.1% to close at $1.35.
    • DICE Therapeutics, Inc. (NASDAQ:DICE) fell 16.5% to close at $18.91. Stifel, last week, initiated coverage on the stock with a Buy rating and a $37 price target.
    • Immatics N.V. (NASDAQ:IMTX) fell 15.2% to close at $10.90.
    • Great Panther Mining Limited (NYSE:GPL) declined 14.1% to close at $0.2028.
    • United-Guardian, Inc. (NASDAQ:UG) fell 12.9% to settle at $12.82. United-Guardian, last month, posted Q2 EPS of $0.14.
    • AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) declined 12.8% to close at $0.1767.
    • T Stamp Inc. (NASDAQ:IDAI) dropped 12.4% to close at $1.55.
    • Nuwellis, Inc. (NASDAQ:NUWE) fell 11.2% to close at $0.7547.
    • Sarcos Technology and Robotics Corporation (NASDAQ:STRC) fell 11% to settle at $3.47.
    • Vertex Energy, Inc. (NASDAQ:VTNR) fell 9.9% to close at $7.83. Vertex Energy announced extension of Mobile Refinery's mechanical completion target to first quarter of 2023.
    • Lesaka Technologies, Inc. (NASDAQ:LSAK) dipped 9.3% to settle at $4.69.
    • MOGU Inc. (NYSE:MOGU) dropped 9.2% to close at $2.36. Mogu’s board of directors, on Friday, authorized a new share repurchase program of up to $10 million of its shares.
    • Apexigen, Inc. (NASDAQ:APGN) fell 8.7% to close at $6.95 as the company announced the presentation of new data from a Phase 2 trial evaluating sotigalimab (sotiga) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.
    • CleanTech Acquisition Corp. (NASDAQ:CLAQ) fell 8.2% to close at $5.60. CleanTech Acquisition and Nauticus Robotics completed business combination to trade under "KITT" effective September 13.
    • Intrepid Potash, Inc. (NYSE:IPI) dropped 8.2% to settle at $43.09.
    • Codere Online Luxembourg, S.A. (NASDAQ:CDRO) fell 6.3% to close at $3.00. Codere Online recently reported Q2 sales results.
    Get the next $AKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX
    $ALLG
    $ANPC
    $ANVS

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Wayfair Inc.
    $W
    2/20/2026$114.00 → $105.00Overweight
    Analyst
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Goosehead Insurance Inc.
    $GSHD
    2/18/2026$69.00Neutral → Overweight
    Piper Sandler
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Ribbon Communications Inc.
    $RBBN
    2/6/2026$2.90Buy → Neutral
    B. Riley Securities
    Sigma Lithium Corporation
    $SGML
    2/3/2026$14.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    SEC Filings

    View All

    SEC Form 6-K filed by Token Cat Limited

    6-K - Token Cat Ltd (0001743340) (Filer)

    2/27/26 4:30:01 PM ET
    $TC
    Real Estate

    Lesaka Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - LESAKA TECHNOLOGIES INC (0001041514) (Filer)

    2/27/26 4:10:37 PM ET
    $LSAK
    Investment Bankers/Brokers/Service
    Finance

    SEC Form S-3ASR filed by Rhythm Pharmaceuticals Inc.

    S-3ASR - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:37:52 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Founder Conine Steven sold $2,125,377 worth of shares (26,950 units at $78.86), decreasing direct ownership by 14% to 169,073 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/27/26 4:50:41 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chief Executive Officer Shah Niraj sold $2,129,850 worth of shares (27,000 units at $78.88), decreasing direct ownership by 14% to 169,137 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/27/26 4:48:18 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    CEO: Southern Africa Mali Lincoln Camagu returned 77,706 shares to the company and was granted 150,000 shares, increasing direct ownership by 18% to 480,755 units (SEC Form 4)

    4 - LESAKA TECHNOLOGIES INC (0001041514) (Issuer)

    2/27/26 4:47:26 PM ET
    $LSAK
    Investment Bankers/Brokers/Service
    Finance

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Bristol-Myers with a new price target

    RBC Capital Mkts initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $60.00

    2/25/26 7:49:08 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst reiterated coverage on Wayfair with a new price target

    Analyst reiterated coverage of Wayfair with a rating of Overweight and set a new price target of $105.00 from $114.00 previously

    2/20/26 10:42:01 AM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

    -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity (HO). This new data set inc

    3/1/26 12:30:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIO Inc. Provides February 2026 Delivery Update

    20,797 vehicles were delivered in February 2026, increasing by 57.6% year-over-year47,979 vehicles were delivered year-to-date in 2026, increasing by 77.3% year-over-yearCumulative deliveries reached 1,045,571 as of February 28, 2026   SHANGHAI, March 01, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its February 2026 delivery results. The Company delivered 20,797 vehicles in February 2026, representing an increase of 57.6% year-over-year. The deliveries consisted of 15,159 vehicles from the Company's premium smart electric vehicle brand NIO, 2,981

    3/1/26 2:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

    IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA's PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies' option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that

    2/27/26 7:00:00 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goldberg Louis bought $250,039 worth of shares (5,575 units at $44.85) (SEC Form 4)

    4 - Goosehead Insurance, Inc. (0001726978) (Issuer)

    2/25/26 7:28:44 PM ET
    $GSHD
    Specialty Insurers
    Finance

    President & CEO Mcclelland Bruce William bought $74,307 worth of shares (37,000 units at $2.01), increasing direct ownership by 3% to 1,516,164 units (SEC Form 4)

    4 - Ribbon Communications Inc. (0001708055) (Issuer)

    2/13/26 11:08:59 AM ET
    $RBBN
    EDP Services
    Technology

    Executive Chairman Mazanderani Ali bought $398,604 worth of shares (91,423 units at $4.36), increasing direct ownership by 4% to 2,416,538 units (SEC Form 4)

    4 - LESAKA TECHNOLOGIES INC (0001041514) (Issuer)

    2/10/26 4:25:08 PM ET
    $LSAK
    Investment Bankers/Brokers/Service
    Finance

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Leadership Updates

    Live Leadership Updates

    View All

    Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

    MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group

    2/27/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rackspace Technology Reports Fourth Quarter and Full Year 2025 Results

    Fourth Quarter Revenue of $683 million, down 0.4% Year-over-Year; 2025 Revenue of $2,686 million, down 2% Year-over-YearFourth Quarter Private Cloud Revenue of $241 million, down 10% Year-over-Year; 2025 Private Cloud Revenue of $990 million, down 6% Year-over-YearFourth Quarter Public Cloud Revenue of $442 million, up 6% Year-over-Year; 2025 Public Cloud Revenue of $1,696 million up 1% Year-over-YearFourth Quarter Cash Flow From Operating Activities of $60 million; 2025 Cash Flow From Operating Activities of $151 million SAN ANTONIO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rackspace Technology, Inc. (NASDAQ:RXT), a leading end-to-end hybrid cloud and AI solutions company, today announc

    2/26/26 8:00:00 AM ET
    $RXT
    Computer Software: Programming Data Processing
    Technology

    Codere Online Reports Financial Results for the Fourth Quarter and Full Year 2025

    The Company delivered a strong set of results, with record net gaming revenueof €224.1 million and Adj. EBITDA of €13.8 million for FY 2025 Total revenue was €57.1 mm in Q4 2025, while net gaming revenue1 was €60.7 mm, 15% above Q4 2024.Mexico revenue was €29.4 mm in Q4 2025, while net gaming revenue was €32.8 mm, 31% above Q4 2024.Adj. EBITDA reached €6.7 mm in Q4 2025, €4.8 mm above Q4 2024.Net loss was €1.8 mm in 2025 versus a net income of €3.9 mm in 2024.Total cash position of €50.0 mm and no financial debt as of December 31, 2025.Outlook for FY 2026: Net gaming revenue of €235-245 mm and Adj. EBITDA2 of €15-20 mm.391 thousand repurchased shares for an aggregate amount of $2.7 mm under

    2/26/26 7:44:15 AM ET
    $CDRO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AKTX
    $ALLG
    $ANPC
    $ANVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/13/24 8:03:28 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care